FM6 656
499
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5 -reductase InhibitionA. Dutta, S. Panja, R.K. Virk, J.Y. Kim, R. Zott, S. Cremers, D.M. Golombos, D. Liu, J.M. Mosquera,
E.A. Mostaghel, C.E. Barbieri, A. Mitrofanova, C. Abate-Shen
This co-clinical study implicates
NKX3.1
status as a predictor of response to
5 -reductase inhibitors, and suggests that specific molecular features, including
NKX3.1
expression, may help to identify prostate cancer patients most likely to
benefit from 5 -reductase inhibitor intervention during active surveillance.
507
Adjunct Screening of NKX3.1 Expression Supports 5 -Reductase Inhibition Intervention in Prostate Cancer Active SurveillanceJ.C. Yang, C.P. Evans
509
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic BiologyS.M. Walker, L.A. Knight, A.M. McCavigan, G.E. Logan, V. Berge, A. Sherif, H. Pandha, A.Y. Warren,
C. Davidson, A. Uprichard, J.K. Blayney, B. Price, G.L. Jellema, C.J. Steele, A. Svindland,
S.S. McDade, C.G. Eden, C. Foster, I.G. Mills, D.E. Neal, M.D. Mason, E.W. Kay, D.J. Waugh,
D.P. Harkin, R.W. Watson, N.W. Clarke, R.D. Kennedy
We have identified a distinct molecular subgroup of primary prostate cancers with
metastatic potential at presentation; a prospective biomarker assay to detect the
group demonstrates significant performance for prediction of biochemical relapse
and metastatic recurrence post surgery in independent validation sets.
519
Prediction is “Still” Difficult when it is About the PastF. Kosari, R.J. Karnes
521
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric OncologyJ.-P. Droz, G. Albrand, S. Gillessen, S. Hughes, N. Mottet, S. Oudard, H. Payne, M. Puts, G. Zulian,
L. Balducci, M. Aapro
Advances in geriatric evaluation and treatments for localised and advanced disease
are contributing to more appropriate management of elderly patients with prostate
cancer. A better understanding of the role of active surveillance for less aggressive
disease is also contributing to the individualisation of care.
532
Prostate Cancer Management in an Ageing PopulationJ.P. Grummet, K. Plass, J. N’Dow
534
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate CancerM. Van Hemelrijck, H. Garmo, L. Lindhagen, O. Bratt, P. Stattin, J. Adolfsson
The potential change from active surveillance (AS) to watchful waiting (WW) should
be discussed with men starting on AS. Our estimations may help in planning health
care resources allocated for men on AS, as there will be less follow-up expenditure
for WW.
542
Active Surveillance: A Ten-year JourneyP.C. Albertsen
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 4 , Oc t o b e r 2 0 1 7
Prostate Cancer